An Improved Convergent Approach for Synthesis of Erlotinib, a Tyrosine Kinase Inhibitor, via a Ring Closure Reaction of Phenyl Benzamidine Intermediate
TLDR
An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer as discussed by the authors.Abstract:
An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized.read more
Citations
More filters
Journal ArticleDOI
Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib.
Marziyeh Fathi,Parham Sahandi Zangabad,Ayuob Aghanejad,Jaleh Barar,Hamid Erfan-Niya,Yadollah Omidi +5 more
TL;DR: The developed smart folate-(PNIPAAm-co-OA)-g-CS micellar NPs could be used for effective cancer therapy as an injectable tumor targeting nanocarrier.
Journal ArticleDOI
Thermo-sensitive chitosan copolymer-gold hybrid nanoparticles as a nanocarrier for delivery of erlotinib.
Marziyeh Fathi,Parham Sahandi Zangabad,Jaleh Barar,Ayuob Aghanejad,Hamid Erfan-Niya,Yadollah Omidi +5 more
TL;DR: Having used thermo-sensitive CS copolymer with free amino groups, CGH NPs were obtained in one-pot procedure, which could be considered as stimuli-responsive delivery system with potential biomedical applications.
Journal ArticleDOI
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
TL;DR: In this article, the authors focused on EGFR small-molecule inhibitors that have been approved for clinical uses in cancer therapy and classified them based on their chemical structures, target kinases, and pharmacological uses.
Journal ArticleDOI
Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends.
Jamileh Kadkhoda,Mohammad Akrami-Hasan-Kohal,Mohammad Reza Tohidkia,Samira Khaledi,Soodabeh Davaran,Ayuob Aghanejad +5 more
TL;DR: In this article, the authors update the recent progress of antibody nanoconjugates to improve early detection and cancer therapy, which is a critical subject and requires precise design and development.
Journal ArticleDOI
Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer
Poorya Najjari Nabi,Nasim Vahidfar,Mohammad Reza Tohidkia,Aliasghar Hamidi,Yadollah Omidi,Ayuob Aghanejad +5 more
TL;DR: In this paper, the authors examined the impact of mucin-1 aptamer-conjugated NPs which were engineered using PAM for image-guided delivery of gefitinib (GEF) in the breast cancer cells/tumor.
References
More filters
Journal ArticleDOI
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor
TL;DR: Combined treatment with distinct EGFR inhibitory agents can augment the potency of EGFR signaling inhibition and this approach suggests potential new strategies to maximize effective target inhibition, which may improve the therapeutic ratio for anti-EGFR-targeted therapies in developing clinical trials.
Journal ArticleDOI
Targeting the epidermal growth factor receptor.
TL;DR: The preliminary results suggest an increase in response rate and time to progression with the combination of cetuximab and chemotherapy in both disease models and the identification of biologic predictors of response, combination with other targeted agents, and their utilisation in earlier stage malignancies.
Journal ArticleDOI
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Carol A. Townsley,Pierre Major,Lillian L. Siu,Janet Dancey,Eric Chen,Gregory R. Pond,Trudey Nicklee,James Ho,David W. Hedley,Ming-Sound Tsao,Malcolm J. Moore,Amit M. Oza +11 more
TL;DR: Erlotinib was well tolerated with the most common toxicities being rash and diarrhoea and correlative studies showed a reduction in phosphorylated EGFR and ERK in tumour tissue post-treatment.
Journal ArticleDOI
Erlotinib in non-small cell lung cancer treatment: current status and future development.
Cesare Gridelli,Maria Anna Bareschino,Clorinda Schettino,Antonio Rossi,Paolo Maione,Fortunato Ciardiello +5 more
TL;DR: Elotinib has shown a significant improvement in median survival, quality of life, and related symptoms in an unselected population of advanced and metastatic NSCLC patients in the second- or third-line setting, and has significant antitumor activity in first-line treatment.
Journal ArticleDOI
Convergent Approach for Commercial Synthesis of Gefitinib and Erlotinib
TL;DR: An efficient, economical and large-scale convergent synthesis of epidermal growth factor receptor- tyrosine kinase inhibitors gefitinib (1, Iressa) and erlotinib(2, Tarceva) is described in this paper.